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Abstract
This MiniReview updates and expands the MiniReview of aluminum toxicokinetics by Wilhelm et al. published by this journal in 1990. The use
of 26Al, analyzed by accelerator mass spectrometry, now enables determination of Al toxicokinetics under physiological conditions. There is concern
about aluminum in drinking water. The common sources of aluminum for the human are reviewed. Oral Al bioavailability from water appears to be about
0.3%. Food is the primary common source. Al bioavailability from food has not been adequately determined. Industrial and medicinal exposure, and
perhaps antiperspirant use, can significantly increase absorbed aluminum. Inhalation bioavailability of airborne soluble Al appears to be about 1.5% in the
industrial environment. Al may distribute to the brain from the nasal cavity, but the significance of this exposure route is unknown. Systemic Al
bioavailability after single underarm antiperspirant application may be up to 0.012%. All intramuscularly injected Al, e.g. from vaccines, may eventually
be absorbed. Al distributes unequally to all tissues. Distribution and renal excretion appear to be enhanced by citrate. Brain uptake of Al may be mediated
by Al transferrin and Al citrate complexes. There appears to be carrier-mediated efflux of Al-citrate from the brain. Elimination half-lives of years have
been reported in the human, probably reflecting release from bone. Al elimination is primarily renal with ≤ 2% excreted in bile. The contribution of food
to absorbed Al needs to be determined to advance our understanding of the major components of Al toxicokinetics.
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I. Overview
This mini-review will update and expand on topics covered by Wilhelm et al. (1990), incorporating recent reviews and original research reports. It
will focus on the pharmacokinetics of Al that influence its potential to produce toxicity from the common sources to which humans are exposed. This will
enable identification of the primary circumstances that might contribute to Al accumulation and toxicity. Research advances in the past decade include
estimates of Al bioavailability under conditions that model drinking water Al consumption and from inhalation and transdermal exposure. This
MiniReview will also address recent studies on the extent of Al distribution to and retention by the brain and bone and the extent of biliary Al excretion.
A significant advance in Al research is the use of
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Al and its analysis by accelerator mass spectrometry (AMS). Their use enables the study of Al

toxicokinetics at physiologically-relevant doses/concentrations.

II. The toxicity, sources, speciation and analysis of Al
Al has been shown in animals and humans to have the potential to be a toxicant to the central nervous, skeletal and hematopoeitic systems
(contributors to Yokel and Golub, 1996 & 1997; Health Canada, 1998; ATSDR, 1999; California EPA, 2000; Cannata Andía, 2000). There are
suggestions of Al-induced nephrotoxicity and pulmonary fibrosis (Jeffery et al. in Yokel & Golub, 1996 & 1997; ATSDR, 1999). Al is a neurotoxicant.
Large elevations in systemic Al from Al-contaminated dialysates and intravenous fluids, oral consumption of large amounts of Al-containing
antacids/phosphate binders by people with significantly impaired or no renal function, and irrigation of the urinary bladder with massive amounts of alum
to stop hemorrhaging can produce an encephalopathy. Encephalopathy from Al exposures that cause large increases in systemic Al has greatly decreased,
but not disappeared, over the past two decades. It has been suggested that low level long-term exposure to Al may be a contributing factor in Alzheimer's
disease (AD) and related disorders. The results of some epidemiological studies of the association between drinking water Al and AD are consistent with
this hypothesis while some others are not (Health Canada, 1998; California EPA, 1999; Yokel, 2000). Similarly, only some of the studies that determined
Al in bulk brain, neurofibrillary tangles and senile plaques of victims of AD and related disorders are consistent with this hypothesis (Yokel, 2000). A
recent study investigating adverse effects on the central nervous system of Al welders found an Al-exposure-related increase in blood and urine Al
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concentrations, deficits in neuropsychological test performance and mild diffuse EEG abnormalities (Riihimäki et al., 2000). The potential for Al-induced
neurotoxicity in those occupationally exposed to Al fumes may be greater than previously suspected. There is developing concern about adverse effects of
Al on neurobehavioral development (Golub and Domingo in Yokel and Golub, 1996 & 1997). This issue has not been extensively investigated. Although
Al contamination of dialysates has decreased over the past two decades, Al is still a major causative agent in the low bone turnover diseases, osteomalacia
and adynamic bone (Cannata Andía, 2000). An initial indicator of elevated systemic Al is often an anemia due to decreased hemoglobin synthesis.
The primary Al sources for the human are in Table 1. Its presence in drinking water derives from natural sources and water treatment methods. Water
treatment generally increases the percentage of dissolved, small molecular weight, chemically reactive, and possibly more readily absorbed, Al species
(LaZerte et al. in Yokel & Golub, 1997; Health Canada, 1998). Although water is the most extensively studied Al source, it provides only about 1% of normal
daily human intake (Table 1). The primary normal source of Al for the human is food (Table 1). The Al content of foods is highly variable (Pennington,
1987; Greger & Surtherland, 1997). The major contributors to the human diet are food products containing Al in food additives, such as grain products,
processed cheese, and salt (Pennington, 1987; Nieboer et al. 1995). Occupational Al exposure occurs primarily in Al processing and welding, and can
significantly increase Al exposure and produce neurotoxicity (Sjögren et al. in Yokel & Golub, 1997; Riihimäki et al, 2000). Al exposure can result from
the use of Al chlorohydrate in antiperspirants. Common iatrogenic sources are vaccines; Al hydroxide, used as both an antacid and a phosphate binder;
and Al contamination in hemodialysis fluids and iv solutions, including total parenteral nutrition solutions (Greger & Sutherland, 1997). As a result of the
concern about Al in the latter, particularly to the very young human, the United States Food and Drug Administration now requires that Al concentrations
be under 25 µg/L in large volume parenteral drug products used in total parenteral nutrition (US FDA, 2000).
Al, as Al3+, is found in various chemical species in the above sources and in vivo. These species have different physical, chemical and biological
properties (Harris et al. in Yokel & Golub, 1996 & 1997). The solubility of Al3+ is lowest at pH 6.2. Acidic and alkaline solutions, as well as some
complexing ligands, increase its solubility. The toxicokinetics of Al species can vary greatly. The information available on Al species from
thermodynamic modeling suggests there are two primary Al species in plasma and one in brain extracellular fluid (Table 2). The effective equilibrium
constant, a ratio of the concentration of all reaction products in solution to the concentrations of the reactants, indicates the affinity of the ligand for Al
4

at pH 7.4. Considerations of Al distribution into tissues and out of the brain should focus on these predominant species. Even though ligand exchange
reactions with Al are slow, there is very little kinetic data on pre-equilibrium Al species.
The naturally occurring isotope of Al is
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Al. It was the only isotope used in Al research until the past decade.

27

Al is ubiquitous. Al is most

commonly quantitated by electrothermal atomic absorption spectroscopy (ETAAS), which has a detection limit of ≤ 1 µg/l. Al contamination can derive
from airborne particulates, reagents used to digest and dilute samples, glass labware and insufficiently cleaned labware of any composition that comes
into contact with the sample. Contamination is often encountered and has rendered many studies useless, particularly those measuring Al in blood and
brain at very low concentrations. Contamination can produce false elevations in the apparent Al concentration. ETAAS determines total Al. Al speciation
requires a separation method prior to Al analysis when ETAAS or another destructive analytical technique is used to quantitate Al. The percentage of Al
absorbed from most exposure routes is very small. Therefore, researchers had to administer amounts of Al that were > 10-fold the human daily Al intake
in food or > 1000-fold the daily Al intake in water to be able to investigate the influence of oral Al intake on Al in blood, urine, or tissue. In the past
decade accelerator mass spectrometry (AMS) has been applied to the quantitation of
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Al (Flarend & Elmore, 1998), enabling the study of extremely

small Al concentrations. A disadvantage is the high cost of AMS analysis.

III. Al bioavailability
Al is absorbed from all routes of exposure that have been investigated. Its bioavailability is very dependent on the route of exposure. This section
will review the major routes of exposure and current estimates of bioavailability.
A. Oral bioavailablity
Oral exposure has been the most extensively studied route of Al absorption. It provides the greatest Al exposure for most people. However, in
selected populations, it is not the route that provides the greatest risk of systemic Al accumulation and toxicity.
1. Methods to determine oral Al bioavailability
Bioavailability (fractional absorption) is the amount absorbed compared to the amount administered. For Al, systemic bioavailability, the
5

fraction that ultimately reaches systemic circulation from which it has access to the target organs of its toxicity, is most relevant. Three methods to
estimate Al bioavailability were discussed by Wilhelm et al. (1990). Method #1 is balance studies. In Method #2 absorption is based on urinary
excretion/dose. Method #3 compares areas under the plasma concentration-time curve after oral and iv administration. A limitation of Method #2 to
estimate bioavailability is that it does not account for the Al that is retained, excreted by non-renal routes, or excreted by the kidneys after study
completion. A number of studies have used urinary Al excretion plus tissue Al to partially overcome this limitation. Another method used in recent human
studies is estimation of absorption from a single blood sample × the estimated volume of distribution, to calculate the % of the dose in plasma. This method
underestimates bioavailability because it does not account for Al that has been excreted prior to sample collection, Al that has distributed out of the vascular
compartment, or the Al that is absorbed after sample collection. The method does not assure peak serum Al was sampled unless independently determined. It
has been concluded that bioavailability estimates based on incomplete blood data have considerable error (Priest et al. 1996). These studies are not included in
this MiniReview.

2. Bioavailability of the Al in drinking water
Several studies have estimated oral Al bioavailability using conditions relevant to Al consumption in drinking water. They used Al doses that
reasonably compare with daily oral intake from water by humans (0.1 mg, ~ 1.5 µg/kg, Table 1) and introduced the Al as a free ion, as might be found in
drinking water, or used water from municipal water suppliers. Results of these studies are shown in Table 3. There are no good data to indicate if Al
bioavailability from water is dose/concentration dependent. These results suggest that oral Al bioavailability from water is in the range of 0.05 to 0.4%;
and most likely ~ 0.3%.
Recognition of Al bioavailability and neurotoxicity lead the U.S. Environmental Protection Agency to put Al on its Contaminant Candidate List
(US EPA, 1998). The Agency felt additional research on Al was needed as part of the consideration for development of drinking water regulations and
guidance. The Canadian Government established an operational guidance value of < 100 µg Al/l in treated water from conventional treatment plants
6

(Health Canada, 1998). California proposed a public health goal for Al in drinking water (California EPA, 2000).

3. Bioavailability of the Al in beverages and foods
Although food comprises the primary source of Al for the typical human (> 90%, Table 1), there are very little data on oral Al bioavailability from
foods, or beverages other than water. It has generally been assumed that oral Al bioavailability from food is less than from water due to Al incorporation
in high molecular weight, relatively insoluble, complexes (Health Canada, 1998). For example, a much lower percentage of the Al in tea was in
chemically labile species, 15%, than in drinking water, 61-75% (Stauber et al. 1999). Reiber et al. (1995) suggested that a substantial portion of Al,
regardless of the chemical species consumed, will be solubilized to monomeric Al in the stomach and subsequently converted to poorly soluble Al species
in the near neutral pH of the upper intestine. As the stomach is not an important site of Al absorption, this implies that oral Al bioavailability should be Al
species independent. Citrate and other ligands influence Al absorption, suggesting this hypothesis is an oversimplification. Stauber et al. (1999) estimated
Al bioavailability from drinking water and food in humans and found it to be comparable from these two sources, ~ 0.3%. Al bioavailability from food
was based on 24-hour urinary Al excretion during the second day of consumption of a controlled diet. This diet provided ~ 3000 µg Al/day, which is
below typical dietary intake (Table 1). Absorption of Al from food consumed prior to the study, which likely provided > 3000 µg Al/day, may have
contributed to the urinary Al excretion during the study. This would produce an over-estimation of Al bioavailability from the controlled diet. Others have
attempted to estimate oral Al bioavailability from food by comparing 1) average daily urinary Al excretion and 2) average daily Al intake from food.
Daily urinary Al excretion has been estimated to be 4-12 µg (Nieboer et al. 1995). Average daily Al intake by adults in the US is estimated to be 500010,000 µg (see Table 1). This suggests an Al bioavailability from food of ~ 0.1%.
If Al bioavailability from the diet is indeed 0.1%, then food, not water, provides the major source of Al absorbed daily (Table 1). Al bioavailability
from water would have to exceed that from food by ~ 50 to 100-fold for water to be the primary source of absorbed Al. The limited published data
suggest that oral Al bioavailability from food is in the same range as from water, suggesting food provides the majority of Al that is absorbed by the
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typical human.

4. The influence of food and dietary components on oral Al absorption
It has been assumed that the presence of food in the stomach inhibits Al absorption, due to Al association with organic ligands in food. Only a few
studies directly addressed this hypothesis. Walton et al. (1994) conducted an ambitious study to assess the influence of beverages and foods on oral Al
absorption. Their results show increased peak serum Al concentration and urinary Al excretion after co-administration with orange juice, and to a much
smaller extent, coffee and wine. Meat and a carbohydrate/cereal product decreased Al absorption. However, neither the blood nor urine samples obtained
hourly for 4 hours after dosing enable determination of oral Al bioavailability. Druecke et al. (1997) reported 0.94% oral 26Al bioavailability in 24-hour
fasted rats versus 0.06% in free-feeding rats. However, rodents and rabbits recycle their feces to increase essential nutrient absorption and usually have
stomach contents 24-36 hours after food removal, suggesting the fasted rats may have had stomach contents. In contrast, Yokel et al. (2001) did not find a
difference in oral 26Al bioavailability in rats exposed to a procedure that resulted in no stomach contents versus rats that did have chow in their stomachs
(Table 3).
The addition of calcium and magnesium carbonates, modeling hard water, did not affect oral Al bioavailability from water (Yokel et al. 2001).
There is not much evidence that food in the stomach or water quality significantly affect oral Al bioavailability. There are also no good reported data from
which one can estimate the relative bioavailability of Al from beverages and food, other than Al plus citrate in solution compared to water, discussed
below.
Health Canada (1998) reviewed the factors affecting Al absorption. They cited evidence that low pH, increased solubility of the Al species, the
presence of citrate and other small organic acids, and uremia increase Al absorption whereas phosphorus and perhaps silicon reduce Al absorption. The
pH can greatly influence Al speciation, and presumably Al bioavailability. The ability of citrate to increase oral Al bioavailability has received much
attention. Three proposed mechanisms; citrate enhanced Al solubility in the gut, transport of Al citrate into mucosal cells, and citrate opening of epithelial
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tight junctions, were reviewed by Greger & Sutherland (1997). The different times of peak serum Al and citrate after Al citrate consumption suggest Al was
not released into blood as Al citrate (Taylor et al. 1998). Other carboxylic acids similarly enhance Al absorption from Al hydroxide, although less effectively.
It has been suggested that this is due to enhanced Al solubility. Phosphate and Al inhibit each other's absorption, due to formation of insoluble Al phosphates.
Conversely, Al absorption increases as solution pH decreases from the nadir of Al solubility. Al fluoride produced higher plasma Al concentrations than Al
chloride (Allain et al. 1996), raising concern about the presence of both Al and F in drinking water. Silicon, as monomeric silicic acid, forms soluble
hydroxyaluminosilicate whereas oligomeric silica forms a more stable complex (Jugdaohsingh et al. 2000). Silicon reduced gastrointestinal absorption of 26Al
(consumed in orange juice, a source of citrate) by 85% in fasted humans (Edwardson et al. 1993). Silicon may abrogate citrate-enhanced Al solubility.
However, Drueke et al. (1997) did not find an effect of co-administered Si on absorption of 26Al given with citrate to rats after eating. Jugdaohsingh et al.
(2000) found inhibition of 26Al absorption by the poorly absorbable oligomeric, but not the absorbable monomeric silica, perhaps explaining the discrepancies
in the above results.

5. The influence of biological factors on oral Al absorption
Uremia appears to increase Al absorption by increasing gut permeability of the paracellular pathway (Greger & Sutherland, 1997). There are
suggestions in the literature that oral Al bioavailability is greater in the weanling than growing rat and increases in the aged and Alzheimer diseased
human. In contrast, oral Al bioavailability was not found to be significantly different between adult humans aged 36-59 versus 59-76 years old (Stauber et
al. 1999). These studies do not provide convincing evidence to resolve the important question whether oral Al bioavailability is age related.

6. Oral bioavailability from drugs
The published data on oral bioavailability of Al species relevant to drugs includes Al hydroxide; the antacid sucralfate; Al lactate, which is used in
dental products for sensitive teeth; and Al in the presence of citrate. As shown in Table 1, antacids/phosphate binders have the potential to produce the greatest
increase of absorbed Al of all Al sources. This presents a problem when these products, which usually contain Al hydroxide, are consumed in large amounts
9

by those who have impaired or no renal function. This practice, along with contaminated dialysate, which is largely avoided today, has produced most of the
cases of Al-induced toxicity. The use of Al hydroxide by renal patients continues in some parts of the world. Citrate and other small carboxylic acids can
increase Al absorption, as noted above.
Wilhelm et al. (1990) cited much of the work conducted with 27Al, which of necessity, used large doses of Al. Priest et al. (1996) estimated oral Al
bioavailability from 6-day urinary 26Al output in 2 subjects. Both received intragastric dosing of 26Al incorporated into Al hydroxide, 26Al hydroxide in the
presence of citrate, and 26Al citrate. Estimates of the percentage of 26Al absorbed from 26Al hydroxide in the absence and presence of citrate averaged 0.01%
and 0.14%, respectively. Al bioavailability from 26Al citrate was 0.52%. These limited results mirror many reports showing very low Al bioavailability from
Al hydroxide (and sucralfate) and augmentation by citrate. Oral Al bioavailability from Al hydroxide appears to be less than from food or water. However, as
noted in Table 1, the daily intake of Al from Al hydroxide-based antacids can greatly exceed that from the diet and water.

7. The site and mechanisms of absorption of ingested Al
The proximal intestine appears to be the primary site of Al absorption (Greger & Sutherland, 1997). Absorption of Al was suggested to be a twostep process, uptake by mucosal cells followed by much slower release into blood (Wilhelm et al. 1990). Evidence that mucous in the gastrointestinal tract
can bind Al, to retard and perhaps inhibit its absorption (Powell et al. 1999), suggests a third-step. Greger & Sutherland (1997) identified the putative
mechanisms of absorption; passive (diffusion) and active (carrier- and vesicular-mediated transport) processes across intestinal cells as well as paracellular
diffusion between these cells. They reviewed the evidence for absorption of Al by paracellular diffusion and active transport. The active processes that have
been suggested to mediate intestinal Al absorption include mechanisms of Ca uptake such as Ca channels, Na transport processes, and a role for transferrin
(Greger & Sutherland, 1997; van der Voet & de Wolff, 1998). The calcium and iron status of the animal inversely influence Al absorption. Transferrin
addition to the vascular perfusion medium of the isolated rat intestine increased vascular Al, suggesting a role for transferrin mediating Al release from
mucosal cells into blood.

10

B. Absorption of inhaled Al
Inhalation exposure results from cosmetic, occupational and environmental Al sources. The only data amenable to Al bioavailability estimates are from
occupational exposure. Occupational exposure to Al fumes, dusts and flakes can elevate serum, bone and urine Al. It is not known if the Al is absorbed from
the lung or from the gastrointestinal tract after mucociliary clearance because experimental studies have not isolated the pulmonary from other absorption
routes. The rapid increase of Al in the serum and urine after Al fume exposure suggested pulmonary absorption (Sjögren et al. 1985). Fractional Al
absorption by industrial employees was ~ 1.5-2%, based on the relationship between urinary Al excretion and the airborne soluble Al to which they were
exposed (Gitelman et al. 1995; Pierre et al. 1995; Sjögren et al. in Yokel & Golub, 1997). Pulmonary Al absorption appears to be more efficient than
gastrointestinal absorption.

C. Intranasal absorption
It has been suggested that Al may directly enter the brain from the nose through olfactory neurons, which run from the roof of the nasal cavity to the
olfactory bulb. Tjälve & Henriksson (1999) reviewed the anatomy of this process and the published studies with metals. Inorganic cadmium, mercury and
nickel were found in the olfactory bulb after their introduction into the rat nasal cavity, but not in other brain regions. This suggests they lack the ability to
cross synapses in the olfactory bulb, to distribute to other neurons. In contrast, manganese was found in numerous brain regions (demonstrating transsynaptic distribution).
Implantation of Gelfoam saturated with Al lactate or Al chloride solution into the nasal recess of rabbits for one month resulted in
neuropathological changes and elevated Al in the brain (Perl & Good, 1987). Limited results in rats exposed to Al chlorohydrate by inhalation showed Al
in brain stem nuclei, also suggesting olfactory nerve uptake and trans-synaptic Al distribution (Divine et al. 1999). However, there are no data that could
be used to estimate Al bioavailability following intranasal exposure to indicate whether this represents a significant route of exposure.

D. Transdermal absorption
11

Al salts, such as Al chlorohydrate, are extensively used in antiperspirants. They suppress eccrine sweating by forming a hydroxide precipitate in
the sweat duct or by denaturing keratin in the cornified layer that surrounds the opening of the sweat duct. Neither mechanism would suggest significant
Al absorption through the sweat duct. A study of Al absorption following single underarm applications of 26Al chlorohydrate to two subjects suggested up
to 0.012% of the 26Al might eventually be absorbed, presumably through the skin (Flarend et al, 2001). It is not known if comparable Al absorption would
continue to occur from daily application, which would determine if this source of Al might significantly contribute to daily Al absorption (Table 1). The
authors suggest that interaction of Al with the sweat duct would reduce subsequent Al absorption.

E. Systemic appearance of Al after parenteral administration
Intravenous Al administration creates the potential risk of Al accumulation and toxicity due to 100% bioavailability and the avid Al binding by
transferrin that prevents rapid clearance. Similarly, exposure to Al-contaminated dialysate can result in diffusion of Al into plasma and its retention by
transferrin. Manifestations of the resulting Al-induced toxicity are described in Health Canada (1998) and California EPA (2000). To ascertain Al
bioavailability following intramuscular injection, and the potential for vaccines to contribute to Al exposure, Flarend et al. (1997) administered
hydroxide or
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Al phosphate adjuvants (which did not contain allergens) to two rabbits. Comparison of blood

26

Al to one rabbit that received iv

26

Al

26

Al

citrate suggested that all of the injected Al may eventually be absorbed, even from these insoluble Al species. Therefore, iv Al exposure from dialysis,
total parenteral nutrition or other solutions as well as intramuscular exposure from the 20 vaccinations given in the first 6 years of life or a typical
treatment regimen of allergen extract immunotherapy could constitute significant sources of absorbed Al (Table 1). The daily Al exposure to dialysis
solution is based on 110 l/dialysis thrice weekly and to total parenteral nutrition solution is based on 0.1 l/kg/day and 2 l/day in neonatal/pediatric and
adult patients, respectively.

IV. Distribution
Al distributes unequally to all tissues throughout normal and Al- intoxicated humans (Alfrey et al. 1980; Di Paolo et al. 1997) and Al-treated
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experimental animals (Greger & Sutherland, 1997). The volume of distribution of Al in animals, reviewed by Wilhelm et al. (1990), suggests an initial
distribution consistent with blood volume. Within blood, Al is ~ equally distributed between plasma and cells. The higher concentration in lung of normal
humans may reflect entrapment of airborne Al particles whereas the higher concentrations in bone, liver and spleen may reflect Al sequestration. The skeletal
system and lung have ~ 50 and 25% of the 30-50 mg Al body burden of the normal human (ATSDR, 1999); brain has ~ 1%. Considering the Al species in
plasma (Table 2), it is likely that Al transferrin and Al citrate account for the majority of the Al that distributes to tissues from the vascular compartment.
Iron status negatively correlates with tissue Al accumulation. This may be due to competition between these two chemically-similar trivalent
cations, enabling greater transferrin-mediated extravascular distribution and ferritin storage of Al in the presence of low iron concentrations (Greger &
Sutherland, 1997).
Al citrate readily distributes out of blood. The effects of citrate on brain and bone Al concentrations and uptake of Al into cells have been inconsistent.
Citrate forms a small molecular weight complex with Al that appears to enhance Al distribution and elimination when compared to Al transferrin (Maitani et
al. 1994). In the presence of renal function, citrate may enhance Al clearance; in renal impairment citrate may enhance tissue Al accumulation.
Calculations show insignificant amounts of Al fluoride species will form in the presence of normal plasma fluoride (~ 100 µg/l) and normal or elevated
plasma Al. This suggests fluoride is unlikely to affect Al distribution or elimination, unless fluoride and Al are involved in mixed ligand complexes involving
other ligands (Wes Harris, personal communication). Similarly, silicon concentrations in biological fluids are very low. It was suggested that it is quite unlikely
monomeric Al silicate species play any significant role in the biological chemistry of Al (Harris et al. in Yokel and Golub, 1996 & 1997).

A. Distribution into and out of the brain
The brain has lower Al concentrations than many other tissues. Increased brain Al is seen in Al-associated neurotoxicity in the human (Alfrey et al.
1980). Studies of AD victims inconsistently showed elevated brain Al (Yokel, 2000), contributing to the controversy concerning a possible role of Al in the
etiology of this disease. Al can enter the brain from blood. This appears to occur by two processes. Roskams & Connor (1990) provided evidence that
transferrin can mediate Al transport across the blood-brain barrier by transferrin-receptor mediated endocytosis (TfR-ME) of Al transferrin, the
13

predominant Al species in plasma (Table 2). Intravenous injection of 26Al transferrin resulted in brain 26Al concentrations (~ 0.003 % of the injected dose/gm
brain) within 4 hours (Yokel et al. 2000). TfR-ME could account for this appearance of Al in the brain if the rate of Al transport is similar to that reported for
Fe. Transferrin increased in vitro Al uptake into neuroblastoma cells and oligodendroglia but not astrocytes (Golub et al. 1999), further suggesting transferrinmediated distribution of Al. Allen et al. (1995) gave Al citrate iv at a rate that produced plasma concentrations in excess of the ability of transferrin to bind the
Al. This presumably permitted Al citrate to be the predominant Al species in plasma. The appearance of Al in brain extracellular fluid (ECF) was too rapid to
be mediated by TfR-ME. This suggests a second mechanism transporting Al citrate across the blood-brain barrier into the brain that is independent of
transferrin.
There appears to be a mechanism to transport Al out of the brain. When Al citrate was infused iv to produce constant brain and blood ECF Al
concentrations, the brain ECF Al concentration was below that in blood ECF (Allen et al. 1995). This suggests a mechanism at the blood-brain barrier to
reduce ECF brain Al by transporting it into blood. Transferrin concentration is very low in cerebrospinal fluid, and presumably brain ECF, whereas the citrate
concentration is higher in brain ECF than in plasma, favoring Al citrate as the predominant Al species in brain ECF (Table 2). It is therefore likely that Al
citrate is the Al species transported out of the brain. Genetic differences or competing ligands for these blood-brain barrier Al influx and efflux carriers may
influence brain Al concentrations.

B. Distribution into and out of bone
Bone Al concentration in normal humans is a few-fold greater than brain Al, on a dry weight basis (Alfrey et al. 1980; Di Paolo et al. 1997). Al
increased more in bone than brain in hemodialysis patients (Alfrey et al. 1980; Di Paolo et al. 1997). Humans with dialysis encephalopathy had brain and
bone Al concentrations about 10- and 85-fold higher than controls, respectively (Alfrey et al. 1980). Several animal studies showed ~ 100-fold higher
bone than brain 26Al concentrations after a single 26Al dose, suggesting greater Al entry into bone than brain. Al concentrates at the mineralization front of
bone.
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V. Elimination rates and tissue retention
Plasma Al half-lives (t½s) were summarized by Wilhelm et al. (1990). Elimination t½s of years were seen after termination of occupational Al
exposure, based on urinary Al excretion (Ljunggren et al. 1991). An estimated terminal t½ in one human who received iv 26Al was 7 years (Priest et al. 1995).
This kinetic behavior might result from retention of Al in a depot from which it is slowly eliminated. This depot is probably bone which stores ~ 50% of the
human Al body burden. Slow Al elimination coupled with continued exposure would be predicted to produce an increasing body burden with age. Brain,
serum and bone Al have been reported to increase with age (Markesbery et al. 1984; Zapatero et al. 1995; Greger & Sutherland, 1997).
There is more than one compartment of Al storage. The t½ of 26Al in rat brain was > 100 days following iv 26Al transferrin dosing (Yokel et al. 2000).
This is consistent with reports suggesting little decrease of brain Al in humans after renal transplantation and termination of the Al that had been given during
renal failure. As noted above, injection of 26Al increased bone 26Al ~ 100-fold more than brain, yet steady state bone Al concentration is < 100-fold that of
brain. This suggests Al clearance from bone is more rapid than from brain, which is reasonable considering bone turnover and lack of neuron turnover.
The elimination t½ of Al from human brain is predicted to be very long. This is concluded from the t½ of Al in the tibia of rats, 38-173 days (Greger &
Sutherland, 1997), compared to > 100 days in brain, above, and a human 26Al t½ of 7 years, above, which is believed to be due to redistribution of Al out
of bone.

VI. Excretion
Urine accounts for > 95% of excreted Al. Reduced renal function increases the risk of Al accumulation and toxicity in the very young, elderly and
renal diseased human (Greger & Sutherland, 1997). Biliary Al accounts for ≤ 2% of total Al elimination in the human, dog, rabbit and rat (Priest et al.
1995; Kovalchik et al. 1978; Yokel et al. 1996; Yokel et al. unpublished results). Chelators can increase Al clearance into urine, bile and dialysate (Yokel
et al. 1996; Yokel et al. in Yokel & Golub, 1996 and 1997). Citrate appears to have chelation properties, to form small molecular weight Al species that
can be excreted in the presence of adequate renal function, potentially protecting against the accumulation and toxicity of absorbed Al.
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VII. Summary
Studies in the past decade, particularly those using physiologically-relevant doses of

26

Al, have refined previous estimates of Al bioavailability

from water and have provided Al biovailability estimates for inhalation, dermal and intramuscular exposure. The contribution of food to daily Al
absorption, compared to other sources, needs to be determined to significantly advance the assessment of the major sources and routes of Al exposure in
the human.
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Table 1. Common sources of Al for the human, Al concentration in the source, resultant daily Al exposure from the source,
estimated bioavailability from the source and calculated amount of Al absorbed daily.
Al
DAILY Al
ESTIMATED
DAILY Al
SOURCE
CONCENTRATION
EXPOSURE
PERCENTAGE
ABSORBED
ABSORBED
(µg/kg)a
Normal Exposure
Average ~ 70 µg/l

100 µg

0.3 b

0.005

Food
Air-rural

0.2 µg/m3

5000-10,000 µg c
4 µg

Air-urban

1 µg/m3

20 µg

Antiperspirants
Vaccines

5-7.5% f

50,000-75,000 µg
1.4-8 µgh

0.1-0.3 d
1.5-2 from lungs e
0.1-0.3 from GI tract
1.5-2 from lungs e
0.1-0.3 from GI tract
up to 0.012 g
100 eventually i

0.08-0.5
0.001
0.0001
0.006
0.0006
up to 0.1
0.07-0.4

up to 5,000,000 µg

0.1

80

Water

150-850 µg/dose

Elevated Exposure
Antacids/phosphate
Binders
Industrial Air
Allergy immunotherapy
Dialysis solution
Total Parenteral
Nutrition Solutions

25-2500 µg/m3

250-25,000 µg per 1.5-2 from lungs e
0.1-0.3 from GI tract
work day
j
100 eventually i
7-40 µg
25 k
2400 µg

0.6-8
0.008-1
0.1-0.6
9

150-850 µg/dose
If tap water 50 µg/l
Neonatal/pediatric
100
11-27
110-270 µg/l l
11-27 µg/kg
l
100
1.2-4.2
Adult 40-135 µg/l
80-270 µg
a
Based on a 65 kg adult except for vaccines (20 kg child) and total parenteral nutrition solution in neonates and pediatrics.
b
From Table 3.
c
Pennington & Schoen (1995).
d
Estimates based on daily urinary Al excretion/daily Al intake from food and Stauber et al. (1999).
e
Based on Al exposure in an industrial setting: Gitelman et al. (1995); Pierre et al. (1995).
f
Based on 20% Al zirconium glycine complex or 25% Al chlorohydrate in a topical product, which are typical concentrations (POISINDEX
information system, Micromedex, Inc, Englewood, CO).
g
Based on Flarend et al. (2001), assuming that the percentage of Al absorbed does not change with repeated exposure.
h
Based on 20 injections in the first 6 years of life and an average weight of 20 kg.
i
Flarend et al. (1997).
j
Based on a typical allergen extract treatment schedule and maintenance injections for 3.5 years of one allergen extract.
k
Kovalchik et al. (1978).
l
Based on maintenance fluids and normal neonatal/pediatric or adult electrolyte supplementation.
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Table 2. The predominant binding ligands for Al in vivo, their effective equilibrium constants with Al, their concentrations in
plasma and brain extracellular fluid (based on values in cerebrospinal fluid), and the percentage of Al predicted to be
associated with that ligand. (Provided by Wes Harris).
LIGAND

Transferrin
Citrate
Hydroxide (free)
Phosphate

EFFECTIVE
EQUILIBRIUM
CONSTANT
WITH Al
(log)
13.7, 12.6
11.6
6.5
9.3

PLASMA

BRAIN EXTRACELLULAR FLUID

CONCENTRATION
(µmol/l)

% OF Al
SPECIES

CONCENTRATION
(µmol/l)

% OF Al SPECIES

30
99
0.4
1100

91
7-8
<1
<1

< 0.25
180
0.4
490

4
90
5
1
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Table 3. Oral Al bioavailability determined in studies that model drinking water consumption.

SUBJECT
Rat
Rat
Rat
Rat

ORAL Al
BIOAVAILABILITY
EXPRESSED AS % by
[METHODa]

Al ADMINISTERED
3.8 ng 26Al + 63 ng 27Al (total Al ~ 0.27 µg/kg)
in distilled water

0.04

3.8 ng 26Al + 63 ng 27Al (total Al ~ 0.22 µg/kg)
in HCl @ pH 1.9

~ 0.1

[2 + bone]

3.8 ng 26Al + 63 ng 27Al (total Al ~ 0.24 µg/kg)

[2 + bone, liver & brain]
0.06

@ pH 1.6-2

[2 + bone @ 48 hrs]

74.5 ng 26Al + 552 ng 27Al (total Al ~ 2.3 µg/kg) @ pH 5

1)
2)
3)
4)
[3]

1 & 2) in dilute HCl
3 & 4) plus 90:1 Ca:Al and 13:1 Mg:Al, as CaCO3 & Mg CO3
1 & 3) no food in stomach

0.23
0.21
0.24
0.41

REFERENCE
Jouhanneau et al.
(1993).
Jouhanneau et al.
(1997).
Drueke et al.
(1997).
Yokel et al. (2001).

2 & 4) food in stomach
Human

100 ng 26Al + 100 µg 27Al (total Al ~ 1.4 µg/kg)

0.1 & 0.24 in 2 subjects

as AlCl3

[2]

Human

141 ng 26Al + 12.5 µg 27Al (total Al ~ 0.2 µg/kg)

0.22

Human

in public water from near Sydney, @ pH 6.5
224 µg 27Al/day for 2 days in pH 7 alum-treated water from a
municipal water treatment plant versus reconstituted soft water
containing <1 µg 27Al/l

[2]
0.36

25

[2]

Hohl et al. (1994).
Priest et al. (1998).
Stauber et al.
(1999).

a

METHODS For details, see 1. Methods to determine oral Al bioavailability.
2 = Bioavailability based on urinary Al excretion/dose.
3 = Bioavailability based on comparison of area under the serum Al concentration × time curve after oral and intravenous
dosing.
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